TreeFrog Therapeutics、シリーズB資金調達で80億円を調達し、米国および日本で幹細胞由来の細胞治療パイプライン開発および独自のC-Stem™技術の展開を推進

TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, today announced the successful closing of a $75 million (€64M) Series B financing round, bringing the total funding to date to $83 million...